Flora Growth (FLGC) Stock Price, News & Analysis

Company Overview

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

Key Stats

• Today's Range: $0.64 to $0.71
• 50-Day Range: $0.62 to $0.99
• 52-Week Range: $0.59 to $2.93
• Volume: 207,757 shs
• Average Volume: 331,802 shs
• Market Capitalization: $13.00 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Moderate Buy

Flora Growth Stock Analysis - MarketRank™

Flora Growth scored higher than 65% of companies evaluated by MarketBeat, and ranked 375th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Flora Growth has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Flora Growth has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Flora Growth are expected to grow in the coming year, from ($0.93) to ($0.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Flora Growth is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Flora Growth is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Flora Growth has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.71% of the float of Flora Growth has been sold short.

Short Interest Ratio / Days to Cover

Flora Growth has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Flora Growth has recently decreased by 23.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Flora Growth does not currently pay a dividend.

Dividend Growth

Flora Growth does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.71% of the float of Flora Growth has been sold short.

Short Interest Ratio / Days to Cover

Flora Growth has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Flora Growth has recently decreased by 23.86%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.19

News Sentiment

Flora Growth has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Flora Growth this week, compared to 1 article on an average week.

Search Interest

7 people have searched for FLGC on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.

MarketBeat Follows

6 people have added Flora Growth to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Flora Growth insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.99% of the stock of Flora Growth is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 36.01% of the stock of Flora Growth is held by institutions.

FLGC Stock Analysis - Frequently Asked Questions

How have FLGC shares performed this year?

Flora Growth's stock was trading at $1.03 at the start of the year. Since then, FLGC stock has decreased by 35.0% and is now trading at $0.6690.
View the best growth stocks for 2025 here.

How were Flora Growth's earnings last quarter?

Flora Growth Corp. (NASDAQ:FLGC) announced its earnings results on Monday, March, 24th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.31. The company had revenue of $13.33 million for the quarter, compared to the consensus estimate of $13.55 million. Flora Growth had a negative trailing twelve-month return on equity of 268.17% and a negative net margin of 30.99%.

When did Flora Growth's stock split?

Flora Growth shares reverse split before market open on Friday, June 9th 2023. The 1-20 reverse split was announced on Friday, June 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Flora Growth IPO?

Flora Growth (FLGC) raised $15 million in an IPO on Tuesday, May 11th 2021. The company issued 3,300,000 shares at a price of $4.00-$5.00 per share. Boustead Securities served as the underwriter for the IPO.

Who are Flora Growth's major shareholders?

Flora Growth's top institutional investors include Geode Capital Management LLC (0.91%), Renaissance Technologies LLC (0.80%), AdvisorShares Investments LLC (0.49%) and Virtu Financial LLC (0.29%). Insiders that own company stock include Harold Wolkin and Clifford Starke.
View institutional ownership trends.

How do I buy shares of Flora Growth?

Shares of FLGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Flora Growth own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Flora Growth investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Tesla (TSLA), NIO (NIO) and

Company Calendar

• Last Earnings: 3/24/2025
• Today: 3/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FLGC
• CIK: 1790169
• Web: floragrowth.ca
• Phone: 954-842-4989
• Fax: N/A
• Employees: 280
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +647.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-57,040,000.00
• Net Margins: -30.99%
• Pretax Margin: -27.13%
• Return on Equity: -268.17%
• Return on Assets: -57.51%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 1.02
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: $59.51 million
• Price / Sales: 0.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.78 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 19,436,000
• Free Float: 12,553,000
• Market Cap: $13.00 million
• Optionable: Not Optionable
• Beta: 1.99